LAG-3

Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.Relatlimab has a blocking effect, blocking the interaction of LAG-3/MHC II (IC50: 0.67 nM) and LAG-3/FGL1 (IC50: 0.019 nM). Relatlimab is often used with Nivoluma to treat advanced melanoma.

Ieramilimab (LAG525) is a humanized antibody targeting LAG-3 with potential anticancer activity, blocking its interaction with MHC-II molecules by binding to LAG-3.Pranlukast hemihydrate can be used to study malignant tumors.

Favezelimab (MK-4280), a humanized monoclonal antibody directed against LAG-3, inhibits the molecular interaction between LAG-3 and its ligand MHC class II, thereby restoring T-cell function. Favezelimab (MK-4280) has been evaluated as a candidate for colorectal cancer (CRC) research, particularly in studies that investigate synergistic effects in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902).

Encelimab, an anti-LAG3 monoclonal antibody, prevents the interaction between LAG-3 and MHC class II molecules, thereby facilitating the activation of T-cells and promoting an enhanced anti-tumor immune response. Encelimab demonstrates efficacy in preclinical models, as it has been observed to reduce tumor burden when administered either as a monotherapy or in conjunction with an anti-PD-1 antibody in lymphoma mouse models, specifically the A20 cell xenograft model.

Fianlimab (REGN3767) is a monoclonal antibody targeting LAG-3 (Lymphocyte Activation Gene 3) in humans, exhibiting antitumor activity. It can be used to study melanoma.

Anti-Mouse LAG-3 is a rat-derived IgG1 antibody inhibitor targeting mouse LAG-3.

Bavunalimab (Anti-Human CTLA4xLAG3), a bispecific human monoclonal antibody targeting CTLA-4 and LAG-3, activates T cells in NSG mice and is utilized in cancer research [1].

Tebotelimab (MGD-013) is a bispecific antibody targeting PD-1 and LAG-3, classified as a human IgG4κ dual-affinity re-targeting (DART) molecule. It has binding affinities with EC50 values of 1.65 nM for PD-1 and 0.41 nM for LAG-3 on NS0 cells. The compound inhibits PD-1/PD-L1, PD-1/PD-L2, and LAG-3/HLA (MHC-II) interactions, as well as PD-1 signaling pathways, thereby reinvigorating exhausted T-cell responses and bolstering antitumor immunity [1] [2] [3].

Cugrastomig is a chimeric antibody of human and humanized IgG1κ-[scFv-heavy -κ]2 type, targeting PDCD1/LAG3.

DNV-3 is a human monoclonal antibody (mAb) that targets CD223/LAG3.

Miptenalimab (BI-754111) is an anti-human LAG-3 antibody with a dissociation constant (K D) of 88.6 nM for h LAG-3, effectively blocking the interaction between LAG-3 and its ligand MHC-II [1].

LAG-3cyclic peptide inhibitor C25 is an inhibitor of LAG-3. It demonstrates a high affinity for human LAG-3 protein with a dissociation constant (Kd) of 0.66 μM. This compound can block the interaction between LAG-3 and HLA-DR (MHC-II), thereby activating CD8+ T cells. LAG-3cyclic peptide inhibitor C25 is applicable in tumor research.

ENUM006 is a human monoclonal antibody (mAb) that targets CD223/LAG3.

GSK2831781 is a human IgG1 monoclonal antibody (mAb) designed to target CD223/LAG3. This compound is applicable in research studies focused on ulcerative colitis. For experimental controls, the recommended isotype control is Human IgG1 kappa.

Brivestobart is a humanized IgG4κ antibody that targets LAG3, accompanied by an isotype control designated as HumanIgG4(S228P) kappa, Isotype Control.

Eftilagimod alfa (IMP321), a recombinant LAG-3Ig fusion protein, binds to MHC class II and mediates the activation of antigen-presenting cells (APCs), which in turn activates CD8 T-cells. It is utilized in the research of metastatic melanoma and metastatic breast carcinoma [1].

LAG-3cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3, exhibiting an IC50 of 4.45 μM and a Ki of 2.66 µM.

Tuparstobart (Incagn-02385) is an IgG1κ monoclonal antibody targeting the immune checkpoint receptor protein LAG-3, predominantly expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells [1].

IMP-761 is a human IgG4 monoclonal antibody (mAb) that targets CD223/LAG3. It binds to the D1 domain of human LAG32. The recommended isotype control is Human IgG4 kappa, Isotype Control.

Alcestobart is a humanized IgG4κ monoclonal antibody targeting LAG3, with HumanIgG4(S228P) kappa serving as its isotype control.

EMB-02 is a bispecific antibody targeting both PD-1 and LAG-3. It inhibits the downregulation of T cell activation and proliferation mediated by PD-1 and LAG-3, showing potent anti-cancer properties.

KL-A289 is a human monoclonal antibody (mAb) that targets CD223/LAG3. It can be utilized in research related to metastatic gastric cancer.

TSR-033 is a human IgG4 antibody with high affinity for LAG-3 (lymphocyte activation gene-3), a co-receptor linked to diminished T cell activity, frequently co-expressed with PD-1. It bolsters T cell function and augments PD-1 inhibition both in vitro and in vivo, demonstrating anti-tumor activity [1].

MEDI-7352 is a human bispecific antibody targeting NGF/bNGF and TNF. It can be utilized in research focused on osteoarthritis (OA) pain.